Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iomab-ACT
NCT04512716Phase 1Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Feb 2021
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of apamistamab in B cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Dose-limiting toxicities and maximum tolerated dose of 131-I apamistamab at 30 days. Started Feb 2021; status: recruiting.
02
Drugs
apamistamab
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04512716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04512716.